This study was undertaken to evaluate the role of a new tumour marker, alone 
In the management of colorectal cancer operative findings, pathological stage and preoperative carcinoembryonic antigen (CEA) levels are strong prognostic indicators that are a guide to the likelihood of cure (Dukes & Bussey, 1958; Wanebo et al., 1978) . However, following potentially curative surgery there is a period of uncertainty as to whether the operation has cured the cancer in an individual patient. Treatment failure will usually become apparent during the first 2-3 years after surgery (Aldridge et al., 1986; Sugarbaker et al., 1987 ).
The precise post-operative surveillance procedures and their frequency vary but are based on clinical assessment, endoscopy, ultrasound and computerised tomography (Cl) depending on the site of primary tumour. Many clinicians will include the measurement of CEA as an essential investigation in the detection of asymptomatic recurre of colorectal cancer. Those surgeons who advocate the use of second-look surgery advise that CEA should be measured every 6-8 weeks so that a suspicious rising level can be identified as early as possible (Staab et al., 1985; Minton & Chevinsky, 1989) ; for others 3 monthly CEA testing during the high-risk period of the first 2 years after resection tends to be the rule with a reduction in frequency of testing thereafter (Hine & Dykes, 1984) .
It is evident that while CEA monitoring during the followup of patients after potentially curative surgery is valuable it lacks the sensitivity and specificity to be an infallible guide to the patient's status (Northover, 1986 (Holmgren et al., 1984) , CA-19-9 (Del Villano et al., 1983) , (Barghava et al., 1987) and CA-242 (Nilsson et al., 1992) , all of which have been shown to be valuable in pancreatic cancer (Kuusela et al., 1991; Taylor et al., 1992; Pasanen et al., 1993) and have been suggested as markers in colorectal cancer. When used in combination with CEA, CA-19-9 (Quentmeier et al., 1987) and (Sagar et al., 1991; Ruggeri et al., 1993) have been shown to provide a gain of positivity in colorectal cancer. The recent studies of showed that it has a higher sensitivity than CA-50 in primary colorectal cancer and a low false positivity in benign liver disease (Kuusela et al., 1991; Nilsson et al., 1992) . In prinary colorectal cancer, additional use of CA-242 improves the diagnostic sensitivity of CEA alone (though it still remains limited) (Roberts et al., 1992) , and CA-242 has also been shown to compklment CEA monitoring of patients reiing chemotherapy for liver metasta from colorectal cancer (Ward et al., 1993 
Results

Recurrent disease
During follow-up there were 25 recurrences in 24 patients (16% of the cohort); one patient had an umbilical recurrence excised and later developed further abdominal wall recurrence and liver metastases. The sites of recurrnce are shown in Figure 1 and the distribution according to Dukes' stage is tabulated in Table II . Recurrent disease occurred in three of the patients with Dukes' A tumours: one developed gross para-aortic lymphadenopathy but no evidence of liver metastasis, while the other two developed metastases in the lung, one also with liver secondaries. In the last two, histological inspection of the excised specimen demonstrated tumour permeation into vascular clefts within the muscularis propria. Both patients with Dukes' D tumours developed recurrence at the site of the distant disease excised at the original operation (the liver in one patient and the pelvis in the other). Twelve of the patients with rectal cancer developed recurrent disease (three locoregional only, one combined local and distant and eight distant disease only). The 13 recurrences in 12 patients with colonic primaries were as follows: three locoregional only, three mixed locoregional and distant and seven distant only. Median time to first recurrence was 17.5 months (range 8-23) for local only recurrences and 14.5 months (range 6-32) for distant or mixed local and distant recurrences.
One patient with pelvic recurrence was treated with radiotherapy and one patient with liver metastasis underwent a course of chemotherapy. Two patients had curative excision of umbilical recurrence. Three patients had elective secondlook surgery and a fourth underwent emergency laparotomy for small bowel obstruction: all had unresectable disease. The only patient with a solitary liver metastasis declined further surgery. The remaining patients with recurrent or metastatic disease were treated symptomatically.
Tumour marker abnormalities During the study period markers were abnormal, as defined above, in 49 patients. Two strategies for the use of CEA and CA-242 in conjunction were adopted, with a positive test being counted either (a) when either marker is abnormal or (b) when both are abnormal. One or other marker was abnormal in 27 of 125 (22%) patients with no recurrence, CEA became abnormal in all patients who developed recurrent disease, either before or after recurrence had been diagnosed. In 17 the abnormality preceded clinical, histological or radiological confirmation of rerrent disease with a median lead time of 5 months (range 1-15). In two patients recurrence and CEA abnormality coincided. CA-242 did not rise to fulfil the criteria of abnormality in two patients with local disease and three patients with distant disease. In 14 it preceded confirmation of recurrence with a median lead time of 5 months (range 1-18).
The parameters quantiffying accuracy of CEA and CA-242 alone or combined in the detection of recurrent (local and/or distant) colorectal carcinoma are shown in Table IV . CA-242 had a lower sensitivity than CEA (60% vs 76%) for recurrent disease. Specificity and positive and negative predictive values were each very similar for CEA and CA-242. Use of the 'either abnormal' strategy leads to a high sensitivity of 88%, a dimunution of specificity to 78% while the false-negative rate (1-negative predictive value) falls to only 3%. For the 'both abnormal' approach the sensitivity falls to only 48% with a rise in specificity, positive predictive value and accuracy. Reports of tumour marker abnormalities depend critically on the criteria used to define the abnormality. For single measurements (e.g. preoperative levels) it is possible to compare the specificity and sensitivity of two tests independently of the cut-off level used to define the abnormality by using receiver operating characteristic (ROC) curve analysis (Pasanen et al., 1993; Zweig & Campbell, 1993 (Beart & O'Connell, 1983; Hine & Dykes, 1984) , some on a trend (Staab et al., 1985; Sugarbaker et al., 1987) , and others using more complicated analytical methods (Martin et al., 1977) . This issue was addressed specifically by Denstman et al. (1986) , but although some form of slope analysis was recommended in preference to an absolute cut-off value no firm guidein could be offered. In tlis study we adopted a definition combining the two decision methods (see section on tumour marker esimation) with emphasis on simplicity and ease of use in a clinical setting. Carcinoembryonic antigen was first described by Gold and Freedman (1965) and for colorectal carcinoma it remains, nearly 30 years later, the gold standard by which new markers are judged. The current study confirms the reliability of CEA levels as a guide to recurrent dis, though there remains the problem, experinced by others (Northover, 1986) , that in 14% of the patients without recurrence there was also an abnormality of CEA (Table Ill) . CA-242 performed very similarly to CEA though with a reduced sensitivity. Neither marker was as good in the detection of local recurrence as distant, though the numbers are too small to make firm conclusions about which test was superior for local disease detection. Although the majority of patients with recurrene had concomitant rise of CEA and CA-242, there were instances in which one marker mained normal while the other rose; thus the use of the two in combination (either abnormal) increased the sensitivity to 88% (Table IV) . This is achieved at the expense of reduced specificity and an increased rate of false positivity. A strategy requiring both markers to be abnormal, while having a high specificty for the detection of recurrence, has an unacceptably low sensitivity of only 48% and is unlikely to be of practical value.
A major drawback of the early diagnosis of recurrent colorectal cancer is the present lack of an effective treatment for the majority of patients. For some, resection of a local recurrene can be curative, and even where there are distant metastases (if few in number) resection may improve prognosis. For the majority of patients, however, early diagnosis may only lengthen the period of anxiety before death. In our cohort only 2 of the 16 patients with recurrent disease underwent potentially curative surgery (both had umbilical disease resected) and one of these remains well 2 years later with no sign of fturther disease. Neither patient had elevated tumour marker levels at diagnosis of recurrence. To take the nihistic view that early diagnosis is of no value, however, would be to negate future advances in treatment and the positive benefits to patients of knowing their destiny.
Initial enthusiasm that CEA-assisted detection of recurrent disease might improve the ability of second-look radical surgery to provide a lasting cure has been tempered by the overall results from some studies (Beart & O'ConnelL 1983) . A multicentre trial in the UK addressing this issue is nearing completion. Previous reports show that only about half the patients who undergo second-look surry have resectable disease, though the proportion who have further potentially curative surgery is higher in patients with asymptomatic recurrene detected by CEA; survival in the latter group is also improved (Minton et al., 1985; Staab et al., 1985; Quentmeier et al., 1990) .
The role of tumour markers extends wider than as an indicator for further surgery. Firstly, the follow-up of colorectal cancer by regular haematological, biochemical and radiological investigation is costly and the majority of investigations are normal (Sugarbaker et al., 1987) . Costeffectiveness may be improved by the use of CEA (or other tumour marker) directed investigation (Wanebo et al., 1989) . Our results show that a normal CEA or CA-242 is rarely seen in the presence of recurrent disease, whereas tumour can eventually be demonstrated in about half the patients in whom either tumour marker is abnormal (positive predictive value 49-51%). This rather low positive predictive value may be considered acceptable given the low false-negative rate. It is clear that CA-242 alone is inferior to CEA as a tumour marker, though it may serve to complement CEA in the follow-up after curative resection for colorectal cancer. In a setting in which investigations were marker directed (as opposed to routine) there might be a significant advantage in having a dual tumour marker assay to give the required high sensitivity, accepting that there may also be an increased negative investigation rate. We are currently examining a larger cohort of patients to evaluate such a policy.
Secondly, specificity of production of the CEA and CA-242 antigens by malignant tissue has opened the possibility for targeting other molecules at the cancer itself by coupling them with antibodies to these epitopes. For example, Pseudomonas exotoxin coupled to C242 (the antibody that recognises the antigen CA-242) has been effective against a human colorectal cancer xenograft in nude mice (Debinski et al., 1992) .
A third, and as yet unexplored, avenue relates to the use of newer therapies directed against recurrent disease. If secondlook surgery has failed to gain general support owing to the relatively small proportion of patients who derive benefit, then perhaps a low-toxicity chemotherapy regimen may prove to be advantageous in patients who develop elevated tumour markers. Currently the American National Institutes of Health (1990) recommends adjuvant chemotherapy (Moertel et al., 1990) 
